The University of Texas MD Anderson Cancer Center

13th Oncology Update: Advances and Controversies

January 16-19, 2015

Sheraton Steamboat HotelSteamboat Springs, Colorado

EDUCATIONAL METHODS Lectures - Question and Answer Sessions – Case Presentations – Meet the Professor Sessions

EVALUATION A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATIONThe University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 25.50 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICS CREDITSSession VI presentations have been designated by The University of Texas MD Anderson Cancer Center for a total of 3.25 AMA PRA Category 1 CreditsTM in medical ethics and/or professional responsibility.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATESCertificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

13th Oncology Update:Advances and ControversiesJanuary 16-19, 2015

GOALThe goal of this program is to provide up-to-date information to the practicing physician regarding new advances in cancer care and treatment.

EDUCATIONAL OBJECTIVESAfter attending the conference, participants should be able to• Interpret information and incorporate into treatment the novel therapies for solid tumors

including Breast Cancer, Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Melanoma, and Sarcoma (Knowledge, Competence, Performance, Patient Outcomes)

• Utilize different surgical, radiation, and systemic treatments including molecularly targeted therapies for these cancers at various stages of disease (Knowledge, Competence, Performance, Patient Outcomes)

• Incorporate appropriate sequence for surgical, radiation, and chemotherapeutic intervention for patients (Knowledge, Competence, Performance, Patient Outcomes)

• Illustrate and implement the optimal treatment approach when given patient scenarios representing a range of stages, prognostic markers, and clinical presentations (Knowledge, Competence, Performance, Patient Outcomes)

• Interpret the clinical effectiveness of the different treatment modalities based upon efficacy and toxicity parameters (Knowledge, Competence, Performance, Patient Outcomes)

TARGET AUDIENCEThis program will be of interest to surgical oncologists, medical oncologists, radiation oncologists, diagnostic radiologists, pathologists, resident trainees, primary care physicians, advanced care practitioners, physician assistants, and nurses involved in oncologic care.

CONFERENCE CHAIRMANMerrick I. Ross, MDProfessor, Surgical OncologyMD Anderson

MD ANDERSON ORGANIZING COMMITTEERae Brana Reynolds, RN, MSNManager, Mid-Level Provider, Surgical OncologyCynthia A. ScottOffice Manager, Surgical OncologyConstance Tierney, CMP Manager, CME/Conference Management

Sheraton Steamboat Hotel • Steamboat Springs, Colorado

The conference will begin with registration from 3:00-5:00 p.m. on Friday, January 16, 2015 followed by a session from 5:00-8:30 p.m. and a Welcome Reception from 8:30-10:00 p.m. All other sessions will run from 7:00 a.m.-1:00 p.m. and 4:30-8:00 p.m. on January 17 & 18, 2015, and from 7:00 a.m.-1:00 p.m. on January 19, 2015.

Program

Friday, January 16, 20153:00–5:00 p.m. Registration

Session I – Breast CancerModerator: Kelly K. Hunt, MD

5:00 p.m. The Art and Science of Genetic Counseling in Breast Cancer Jennifer Litton, MD

New Paradigms in the Surgical Management of the Regional Lymph Nodes in Breast Cancer Kelly K. Hunt, MD

Selective Use of Adjuvant Therapy: Have the New Markers Helped? Funda Meric-Bernstam, MD

Update on Triple Negative and Inflammatory Breast Cancer Jennifer Litton, MD

Recurrent HER-2 Breast Cancer: Beyond Trastuzumab Vicente Valero, MD

Update on Post-Mastectomy Radiation: Are the Indications Evolving? Thomas A. Buchholz, MD

Reconstruction Options in Patients Who Have Received Post-Mastectomy Radiation

Melissa A. Crosby, MD

Keynote PresentationCancer Vaccines: Breast Cancer and BeyondElizabeth A. Mittendorf, MD

Question and Answer/Case Presentations All Session Faculty

8:30-10:00 p.m. Welcome Reception

Saturday, January 17, 2015 6:30 a.m. Registration/Continental Breakfast

Session II – MelanomaModerator: Merrick I. Ross, MD

7:00 The Cancer Genome Project for Melanoma: What Have We Learned? Jeffrey E. Gershenwald, MD

Prognostic Factors Linked to Adjuvant Therapy: Any New Paradigms? Merrick I. Ross, MD

Treatment of Stage IV Disease: The Art and Science of Decision-Making Patrick Hwu, MD

Oncolytic Immunotherapy: Real Systemic Impact Or Just Another Intra-Lesional Therapy?

Robert H. Andtbacka, MD

Reconstruction After Definitive Surgical Treatment David M. Adelman, MD

Question and Answer/Case Presentations All Session Faculty; Victor G. Prieto, MD, PhD; Aysegul Sahin, MD

Noon Meet the Professor – Melanoma Surgical and Medical Oncologists

1:00 p.m. Session Adjourns

Session III – GI CancerModerator: Robert A. Wolff, MD 4:30 p.m. Systemic Therapy for Pancreas Cancer: Neo-Adjuvant or Adjuvant? Robert A. Wolff, MD

Xenograft Models in Pancreas Cancer: Impact on Future Therapies Jason B. Fleming, MD

Controversies in the Multimodality Management of Gastric Cancer Keith F. Fournier, MD

Advances in Colorectal Surgery: Perspectives on Open vs Laparoscopic vs Robotic Surgery

Y. Nancy You, MD

Radiation Therapy for Rectal Cancer: Routine or Selective Use? Christopher Crane, MD Resection of Colorectal Liver Metastases: Still the Standard of Care? Steven A. Curley, MD

Question and Answer/Case Presentations All Session Faculty

8:00 p.m. Session Adjourns

Sunday, January 18, 20156:30 a.m. Registration/Continental Breakfast

Session IV – UrologyModerator: Christopher G. Wood, MD

7:00 a.m. Debate 1: What is the Best Way to Perform a Radical Cystectomy for Muscle Invasive Bladder Cancer: Open Surgery - Jay B. Shah, MD Robotic Surgery - Neema Navai, MD Robotic RPLND for Stage 1 High Risk Testis Cancer: Fad, Folly, or Standard of Care? Brian F. Chapin, MD Debate 2: What is the Most Appropriate Treatment for Stage T1b/T2 Renal Cell Carcinoma? Radical Nephrectomy - Christopher G. Wood, MD Partial Nephrectomy - Jose A. Karam, MD What is the Role of Control of the Primary Tumor in

Metastatic Prostate Cancer? Brian F. Chapin, MD Proton Therapy for Prostate Cancer: Expensive Gimmick or Real Benefit? Andrew K. Lee, MD Question and Answer/Case Presentations All Session Faculty Meet the Professor

Urology

Noon Session Adjourns

Session V – Thoracic OncologyModerator: Stephen G. Swisher, MD

4:30 p.m. Current Recommendations for Lung Cancer Screening: Are We Making Any Progress? Stephen G. Swisher, MD Treatment of Primary Lung Cancer: Surgery or Stereotactic Radiation David C. Rice, MD; Quynh N. Nguyen, MD The Evolving Landscape of Systemic Therapy for Advanced

Non-Small Cell Lung Cancer: The Impact of Molecular Analysis and the Emergence of Anti-PD-1 Therapy

John V. Heymach, MD Multimodality Therapy for Advanced Esophageal Cancer Wayne L. Hofstetter, MD Update on the Role for Endobronchial Ultrasound in the Management of Lung Cancer David C. Rice, MD Question and Answer/Case Presentations All Session Faculty

7:30 p.m. Session Adjourns

Monday, January 19, 20156:30 a.m. Registration/Continental Breakfast

Session VI – EthicsModerator: Merrick I. Ross, MD

7:00 a.m. Outcome Parameters in Cancer Care Karl Y. Bilimoria, MD

Surgical Management of Lymphedema Edward I. Chang, MD

Palliative Surgery: How Do We Measure Success? Brian D. Badgwell, MD

Question and Answer/Case Presentations All Session Faculty

Session VII – HPV SymposiumModerator: Michael E. Kupferman, MD

10:30 The HPV Moon Shot: Grouping Cancers by Etiology Rather Than Anatomy Erich M. Sturgis, MD

Robotic Surgery for HPV Head and Neck Cancer Michael E. Kupferman, MD

Cervical Cancer Prevention Kathleen M. Schmeler, MD

Keynote PresentationSurgery or Gamma Knife for Brain MetastasesJeffrey S. Weinberg, MD

Session VIII – Peritoneal MalignanciesModerator: Michael Frumovitz, MD

Noon Multimodality Treatment for Ovarian Cancer Michael Frumovitz, MD

Is There a Benefit for HIPEC in the Management of Peritoneal Carcinomas? Keith F. Fournier, MD

1:00 p.m. Session Adjourns

REGISTRATION INFORMATIONOn-site registration for the 13th Oncology Update: Advances and Controversies, will open at 3:00 pm on Friday, January 16, 2015, and the conference will begin at 5:00 pm on Friday, January 16, 2015, followed by a Welcome Reception. The conference will adjourn at 1:00 pm on Monday, January 19, 2015. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 5, 2015.

There are three ways to register:• Mail to CME/Conference Management – Unit 1781, The University of Texas

MD Anderson Cancer Center, P. O. Box 301407, Houston, TX 77230-1407.• Fax to 713-794-1724• Register on-line at www.mdanderson.org/conferences

We accept the following forms of payment:• Check (payable through U.S. banks only)• Money order• Credit cards (MasterCard, VISA, and American Express)• Cash (on-site registration only)

When registering on-line a receipt/confirmation letter will automatically be e-mailed to the e-mail address you list on the registration form. If you register by fax or mail a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee.

The conference registration fee includes the tuition, final program, continental breakfasts, coffee breaks, and welcome reception.

REFUND/CANCELLATION POLICYThe registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 5, 2015. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or 1-866-849-5866.

David M. Adelman, MDAssistant ProfessorPlastic Surgery

Brian D. Badgwell, MDAssistant ProfessorSurgical Oncology

Thomas A. Buchholz, MDEVP & Physician-in-ChiefProfessorEVP Physician-in-Chief

Edward I. Chang, MDAssistant ProfessorPlastic Surgery

Brian F. Chapin, MDAssistant ProfessorUrology

Christopher Crane, MDProfessorRadiation Oncology

Melissa A. Crosby, MDAssociate ProfessorPlastic Surgery

Jason B. Fleming, MDProfessorSurgical Oncology

Keith F. Fournier, MDAssistant ProfessorSurgical Oncology

Michael Frumovitz, MDAssociate ProfessorGynecologic Oncology & Reproductive Medicine

Jeffrey E. Gershenwald, MDProfessorSurgical Oncology

John V. Heymach, MDChair & Associate ProfessorThoracic/Head & NeckMedical Oncology

Wayne L. Hofstetter, MDAssociate ProfessorThoracic & Cardiovascular Surgery

Kelly K. Hunt, MDProfessorSurgical Oncology

Patrick Hwu, MDProfessorMelanoma Medical Oncology

Jose A. Karam, MDAssistant ProfessorUrology

Michael E. Kupferman, MDAssociate ProfessorHead & Neck Surgery

Andrew K. Lee, MDProfessorRadiation Oncology

Jennifer Litton, MDAssistant ProfessorBreast Medical Oncology

Funda Meric-Bernstam, MDProfessorSurgical Oncology

Elizabeth A. Mittendorf, MDAssociate ProfessorSurgical Oncology

Neema Navai, MDAssistant ProfessorUrology

Quynh N. Nguyen, MDAssistant ProfessorRadiation Oncology

Victor G. Prieto, MD, PhDChair, Ad interim & ProfessorPathology Administration

David C. Rice, MDProfessorThoracic & Cardiovascular Surgery

Merrick I. Ross, MDProfessor Surgical Oncology

Aysegul A. Sahin, MDProfessorPathology Administration

Kathleen M. Schmeler, MDAssociate ProfessorGynecologic Oncology & Reproductive Medicine

Jay B. Shah, MDAssistant ProfessorUrology

Erich M. Sturgis, MDProfessorHead & Neck Surgery

Stephen G. Swisher, MDChair & ProfessorThoracic & Cardiovascular Surgery

Vicente Valero, MDProfessorBreast Medical Oncology

Jeffrey S. Weinberg, MDAssociate ProfessorNeurosurgery

Robert A. Wolff, MDChair Ad Interim & ProfessorInvestigational Cancer Therapeutics

Christopher G. Wood, MDProfessorUrology

Y. Nancy You, MDAssistant ProfessorSurgical Oncology

MD Anderson Faculty

GuestFacultyRobert H. Andtbacka, MDAssistant ProfessorDivision of Surgical OncologyUniversity of Utah School of MedicineHuntsman Cancer InstituteSalt Lake City, Utah

Karl Y. Bilimoria, MDAssistant Professor, SurgeryNorthwestern UniversityFeinberg School of MedicineChicago, Illinois

Steven A. Curley, MDProfessorMichael E. DeBakey Department of SurgeryBaylor College of MedicineHouston, Texas

ACCOMMODATIONS• A block of rooms has been reserved for conference attendees at the Sheraton

Steamboat Hotel, 2220 Village Inn Court, Steamboat Springs, Colorado.

• Early hotel reservation is suggested.

• The hotel phone number is 1-800-848-8877

• Website: https://www.starwoodmeeting.com/StarGroupsWeb/res?id=1409245371&key=1AA6BBEB

• When you make reservations, be sure to mention the MD Anderson 13th Oncology Update: Advances and Controversies Conference to be assured of receiving the special meeting rate of $239.00. Condos and suites are available. Call hotel for rates. Please add 11.65% state and local taxes.

• Reservations and deposits received after December 18, 2014, will be confirmed if space is available and at currently published hotel guest room rates.

Rooms are guaranteed 30 days prior to arrival by taking a full deposit of the entrie stay. Upon the taking of the deposit all reservations are unchangeable. If cancelled the deposit is non-refundable.

SKI EQUIPMENT RENTAL• Ski rentals are available through https://www.steamboat.com/estore_996/Default.aspx

and enter the group code: SHMD. You will receive a 35% discount when booked in advance and a 30% discount on site.

• Lift ticket discount is 5%. Coupons will be available at registration.

GROUND TRANSPORTATIONThe Sheraton Steamboat Hotel is 22 miles from the Yampa Valley Regional Airport in Hayden (locator code: HDN) and is served by United, Delta, Northwest, and American Airlines. Transportation from the Yampa Valley Regional Airport is available by GO Alpine Airport Shuttle at $35.20/person one way or $55.00/person round trip. Advance reservations are strongly suggested, since walk-up passengers are boarded on a space available basis only. Reservations can be made on-line up to 48 hours beforehand at www.alpinetaxi.com or by phone at 1-800-343-7433.

SPECIAL ASSISTANCEContact the Department of CME/Conference Management at 713-792-2223 or 1-866-849-5866 if you have any special dietary or ADA accommodation needs.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

REG

ISTR

ATIO

N F

EES

13th

Onc

olog

y U

pdat

e: A

dvan

ces

and

Co

ntro

vers

ies,

Jan

uary

16–

19, 2

015

Phys

icia

ns 1

Pos

tmar

ked

befo

re 1

/5/1

5 ....

......

......

$550

.00

1 P

ostm

arke

d af

ter 1

/5/1

5 ....

......

......

...$6

00.0

0

MD

Ande

rson

Fac

ulty

1 P

ostm

arke

d be

fore

1/5

/15 .

......

......

...$3

50.0

0 1

Pos

tmar

ked

afte

r 1/5

/15 .

......

......

......

$375

.00

Fello

ws,

Phy

sici

an A

ssis

tant

s,Nu

rses

, Soc

ial W

orke

rs 1

Pos

tmar

ked

befo

re 1

/5/1

5 ....

......

......

$250

.00

1 P

ostm

arke

d af

ter 1

/5/1

5 ....

......

......

...$2

75.0

0

CO

NFE

RE

NC

E R

EG

IST

RA

TIO

N -

176

700/1116

07

13th

Onc

olog

y Upd

ate:

Ad

vanc

es a

nd C

ontr

over

sies –

Janu

ary 1

6–19

, 201

5

TH

IS IS

NOT

A S

ELF-

MAI

LER

ADDR

ESS

TO:

13th

On

colo

gy

Up

dat

e:

Ad

van

ces

and

Co

ntr

ove

rsie

sDe

partm

ent o

f CM

E/Co

nfer

ence

Man

agem

ent–

Unit

1781

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

PO B

ox 3

0140

7, H

oust

on, T

X 77

230-

1407

or fa

x to

713

-794

-172

4

Mak

e ch

eck

or m

oney

ord

er p

ayab

le to

:Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Last

Nam

e

Fi

rst

M

I

H

ighe

st D

egre

e

Depa

rtmen

t (in

clud

e bo

x no

.)

Sp

ecia

lty

Inst

itutio

n

Ph

ysic

ian

Stre

et

City

S

tate

/For

eign

Cou

ntry

/Zip

or M

ail C

ode

Dayt

ime

Phon

e (w

ith a

rea

code

)

Cel

l Pho

ne (w

ith a

rea

code

)

F

ax (w

ith a

rea

code

)

E-m

ail A

ddre

ss (

plea

se p

rint)

Char

ge th

e fo

llow

ing:

oVI

SA

o

Mas

terC

ard

oAm

eric

an E

xpre

ss

Cred

it Ca

rd N

umbe

r

Exp

iratio

n Da

te

Busi

ness

Uni

t

D

epar

tmen

t

Fun

d Gr

oup*

F

und

F

und

Type

Cred

it Ca

rd H

olde

r Nam

e (F

irst/

Last

)

Cre

dit C

ard

Hold

er B

illin

g Ad

dres

s &

ZIP

Cod

e

Auth

orize

d Si

gnat

ure

REQU

IRED

for c

redi

t car

d or

IDT

MD

Ande

rson

Em

ploy

ee ID

No.

(REQ

UIRE

D)

IDT

Appr

over

Nam

e (F

irst/

Last

) ple

ase

prin

t

I

DT A

ppro

ver E

-mai

l

oYe

s

o

No

MD

And

erso

n In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

: *F

und

Grou

p 90

will

not

be

acce

pted

Emer

genc

y Co

ntac

t

Ph

one

(with

are

a co

de)

Depa

rtm

ent o

f CM

E/Co

nfer

ence

Man

agem

ent -

Uni

t 178

1Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r#1

7670

0/30

/111

607/

41 –

PS1

0083

5PO

Box

301

407

Hous

ton,

TX

7723

0-14

07

Non

-Pro

fit O

rg.

U.S

. Pos

tage

P A

I D

Hou

ston

, TX

Per

mit

No.

705

2